Track the Sagimet Biosciences Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €648.3m. The latest transaction was filed on 17 August 2026 (Levée d'options). Among the most active insiders: Kemble George. Every trade is openly available.
48
Insider Decl.
n/a
Thresholds
€66,172
3 ops.
Buy Volume
€5m
19 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Sagimet Biosciences Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$28.60.
55Σ signal
Buys €66,172€5m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
116,000 shares0Series A Common StockSEC:0001104659-25-010587:0
25 of 48 declarations
Acerca de Sagimet Biosciences Inc.
Sagimet Biosciences Inc. es una empresa biofarmacéutica centrada en el desarrollo de tratamientos innovadores para enfermedades metabólicas. La empresa cotiza en NASDAQ bajo el símbolo SAGE.